Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 4/20 | 0.69 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.69 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.69 |
| ▸ | USP2 | O75604 | 2/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.69 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.69 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.69 |
| ▸ | MEN1 | O00255 | 2/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.69 |
| ▸ | TP53 | P04637 | 1/20 | 0.69 |
| ▸ | GLA | P06280 | 1/20 | 0.69 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.69 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | ABL1 | P00519 | 9/20 | 0.53 |
| ▸ | BCR | P11274 | 9/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | MAPK10 | P53779 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4666194 | 0.85 | TP53 (0.61) | CYP1A2CYP2C19CYP2D6CYP3A4MAPK1 | |
| SCHEMBL4666050 | 0.82 | ABL1 (0.71) | CYP1A2CYP2C19CYP2D6CYP3A4MAPK1 | |
| SCHEMBL4104097 | 0.82 | CYP1A2 (0.51) | CYP1A2CYP2C19CYP2D6CYP3A4MAPK1 | |
| SCHEMBL4109259 | 0.82 | MEN1 (0.66) | MEN1KMT2AABL1BCRNPC1 | |
| SCHEMBL3399322 | 0.81 | ABL1 (0.77) | MAPK1ABL1BCR | |
| SCHEMBL6027404 | 0.81 | CYP1A2 (0.63) | CYP1A2CYP2C19CYP2D6CYP3A4MAPK1 | |
| SCHEMBL4103913 | 0.80 | CYP1A2 (0.52) | CYP1A2CYP2C19CYP2D6CYP3A4MAPK1 | |
| SCHEMBL374096 | 0.79 | CDK5 (0.61) | CYP1A2CYP2C19CYP2D6CYP3A4MAPK1 | |
| SCHEMBL13336486 | 0.76 | ASIC3 (0.66) | CYP1A2CYP2C19CYP2D6CYP3A4MAPK1 | |
| SCHEMBL4114258 | 0.75 | ABL1 (0.51) | CYP1A2CLK4MEN1KMT2ATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080242681-A1 | N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors | ALTANA PHARMA AG (DE) | 2008-10-02 | — | — | US | disclosed |
| US-20080242681-A1 | N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors | ALTANA PHARMA AG (DE) | 2008-10-02 | — | — | US | disclosed |
| US-20080242681-A1 | N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors | ALTANA PHARMA AG (DE) | 2008-10-02 | — | — | US | disclosed |
| EP-1709007-A1 | N-4-(6-(HETEO)ARYL-PYRIMIDIN-4-YLAMINOPHENYL)-BENZENESULFONAMIDES AS KINASE INHIBITORS | Altana Pharma AG (DE) | 2006-10-11 | — | — | EP | disclosed |
| WO-2005070900-A1 | N-4-(6- (HETEO) ARYL-PYRIMIDIN-4-YLAMINOPHENYL) -BEZENESULFONAMIDES AS KINASE INHIBITORS | ALTANA PHARMA AG (DE) | 2005-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242681-A1 | N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors | MAP3K19, MAP3K6, MAP3K20 | CYP1A2 1215/4885CYP2C19 961/4885CYP2D6 646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.